10 percent urea cream superior to new ointment for hand-foot syndrome

the ONA take:

According to a new study published online ahead of print in the Journal of Clinical Oncology, researchers have found that 10% urea cream is superior to a newly introduced ointment containing various antioxidants at preventing hand-foot syndrome during the first 6 weeks of treatment with capecitabine for gastrointestinal or breast cancer.

For the phase III trial, researchers enrolled 152 patients with gastrointestinal tumors or breast cancer who were treated with oral capecitabine. Participants were randomly assigned to receive urea cream or the new ointment, which has been available on the German market since 2011.

Results showed that 30.9% of patients who received the new ointment experienced hand-foot syndrome compared with 22.4% in the urea cream group (OR = 2.37; P=0.02).

Researchers found that time to any-grade hand-foot syndrome was significantly longer in the urea cream arm than the new ointment arm (P=0.03). The study also demonstrated that skin-related quality of life was significantly worse in the new ointment group than the urea group at the end of study treatment.

Access to breast-conserving therapy still an issue for some patients
10% urea cream is superior to a newly introduced ointment containing various antioxidants at preventing hand-foot syndrome.
This study compares a newly introduced ointment containing several antioxidants and exhibiting high radical protection factor, which has been available on the German market since 2011, with urea cream for prevention of HFS in patients treated with capecitabine.
READ FULL ARTICLE From Ascopubs
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs